secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2026-07-22T21:19:38+00:00
Accession:  0001193125-26-312571
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Therapeutics prices upsized $375M public offering of 18.3M shares at $20.50/share
--------------------------------------------------------------------------------

- Offering of 18,300,000 shares at $20.50/share; gross proceeds $375.15M.
- Net proceeds estimated at $352.1M, or $405.0M if underwriters' option exercised.
- Underwriters granted 30-day option to purchase up to 2,745,000 additional shares.
- Closing expected July 23, 2026; proceeds extend cash runway into Q2 2028.
- Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital, Raymond James are joint book-runners.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000119312526312571/0001193125-26-312571-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000119312526312571/d112911d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-312571

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer